✦ LIBER ✦

Steatosis: Co-factor in other liver diseases

✍ Scribed by Elizabeth E. Powell; Julie R. Jonsson; Andrew D. Clouston

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 253 KB
Volume: 42
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.20750

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum hepatocyte growth factor levels in

Serum hepatocyte growth factor levels in liver diseases: Clinical implications

✍ Goshi Shiota; Jun-Ichi Okano; Hironaka Kawasaki; Tomokazu Kawamoto; Toshikazu Na 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 793 KB

## Clinical Implications GOSHI SHIOTA,' JUN-ICHI OKANO,' HIRONAKA KAWASAKI,' TOMOKAZU KAWAMOTO,' AND TOSHIKAZU NAKA1LIURA3 Although recent studies have shown that hepatocyte growth factor (HGF) is a potent mitogen in uiuo, the significance of serum HGF in liver diseases remains unclear. To clarif

Anti-gamma globulin factors in liver dis

Anti-gamma globulin factors in liver disease

✍ Lorenzo Bonomo; Joseph Lospalluto; Morris Ziff 📂 Article 📅 1963 🏛 John Wiley and Sons 🌐 English ⚖ 673 KB

## Abstract Sera from patients with liver disease, showing positive reactions with human Fraction II (F‐II) were submitted to cation exchange chromatography. Rheumatoid factor‐like material, reacting only with F‐II and F‐II sensitized systems, was eluted at pH 6.0 and pH 7.0. In rheumatoid sera, ac

Interleukin 6 alleviates hepatic steatos

Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease

✍ Feng Hong; Svetlana Radaeva; Hong-na Pan; Zhigang Tian; Richard Veech; Bin Gao 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 497 KB 👁 1 views

Fatty liver, formerly associated predominantly with excessive alcohol intake, is now also recognized as a complication of obesity and an important precursor state to more severe forms of liver pathology including ischemia/reperfusion injury. No standard protocol for treating fatty liver exists at th

Fibroproliferation in liver disease: Rol

Fibroproliferation in liver disease: Role of monocyte factors

✍ Dr. Theresa C. Peterson; Richard A. Isbrucker 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 771 KB

Fibroproliferation was measured as the uptake of t3Hlthymidine into fibroblasts. Human fibroblasts were incubated with 200 p1 monocyte-conditioned medium, the 0.22 pm filtrate from cultured monocytes, in Dulbecco's modified Eagle medium supplemented with controlled process serum replacement 2, a fet

Immunohistochemical detection of transfo

Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases

✍ Peter Nagy; Zsuzsa Schaff; Károly Lapis 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 1004 KB

Transforming growth factor-$, was localized by means of immunohistochemical reaction in liver biopsy specimens taken from patients having different chronic liver diseases with extending fibrosis. Two polyclonal antibodies that were produced in rabbits were directed against the amino terminal of tran

Portal fibrosis and hepatic steatosis in

Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease

✍ Gary A. Abrams; Sachin S. Kunde; Audrey J. Lazenby; Ronald H. Clements 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead to hepatic fibrosis and cirrhosis. Portal fibrosis in the absence of NASH, called isolated portal fibrosis (IPF), has received less attention and has not been classified as a spectrum